-
Incidence of Intracerebral Hemorrhage in Patients With Mild Cognitive Impairment or Alzheimer’s Dementia in United States Veterans
Sep 9, 2025, 16:22 PM -
Provisional Listing of Digital Healthcare Applications Digas Improves Patients' Access to Healthcare in Germany
Sep 9, 2025, 16:22 PM -
Reported Herpes Zoster Incidence Rates in Immunocompromised Adults Aged 18 Years or Older in England by Ethnicity and Socioeconomic Status: A Large Retrospective Cohort Study
Sep 9, 2025, 16:22 PM -
Integrating Health Equity Into Health Technology Assessment: A Scoping Review
Sep 9, 2025, 16:22 PM -
Cost-Effectiveness Analysis of Entrectinib in First-Line Treatment for NTRK Locally Advanced or Metastatic NSCLC in China
Sep 9, 2025, 16:22 PM -
Automation-Only Is NOT AI: Beware, HEOR Colleagues
Sep 9, 2025, 16:22 PM -
Health Economic Analysis of Risk- and Age-Based Pneumococcal Vaccination With PCV21 vs. PCV20 in France
Sep 9, 2025, 16:22 PM -
Clinical and Economic Factors Underlying QALY Weights and Severity Modifiers in NICE Health Technology Evaluations: An Analysis of Recent Appraisals
Sep 9, 2025, 16:22 PM -
Overall Survival With Second-Generation Androgen-Receptor Signaling Inhibitors in Patients With Metastatic Castration Resistant Prostate Cancer: An Umbrella Review
Sep 9, 2025, 16:22 PM -
Detection of a Novel Safety Signal for Atorvastatin Potential Association With Hilar Lymphadenopathy Using FAERS Disproportionality Analysis and Molecular Docking
Sep 9, 2025, 16:22 PM -
Exploring the Use and Perception of Patient-Reported Outcome Evidence Among Cardiologists and Patients With Heart Failure
Sep 9, 2025, 16:22 PM -
What Counts? Exploring Stakeholder Perspectives on the Value of Guiding Criteria for Prioritizing Public Funding of Health Technologies
Sep 9, 2025, 16:22 PM -
Clinical Evidence Quality in Appraisals of Drugs for Rare Diseases in England and Germany
Sep 9, 2025, 16:22 PM -
Evaluating an Automated AI-Driven Pipeline for Literature Surveillance and Synthesis: A Proof-of-Concept for Health Economics and Outcomes Research (HEOR) Communications
Sep 9, 2025, 16:22 PM -
Impact of Indirect Treatment Comparison (ITC) Methodology on Cost-Effectiveness of Quizartinib in Acute Myeloid Leukemia (AML) in Canada and the United Kingdom (UK)
Sep 9, 2025, 16:22 PM -
Safety Profile of Semaglutide in Obesity Management With or Without Type 2 Diabetes (T2DM): A Systematic Literature Review From Controlled and Real-World Settings
Sep 9, 2025, 16:22 PM -
Medicare Reimbursements Following Confirmatory MRI-Guided Biopsy vs. Systematic Biopsy Only in Low-Risk and Favorable Intermediate-Risk Prostate Cancer: A Real-World Cost Analysis Among Elderly Medicare Beneficiaries
Sep 9, 2025, 16:22 PM -
Explaining Psychiatric Comorbidities in Patients With Skin Conditions: The Importance of Clinical Characteristics and Patient-Reported Disease Impact
Sep 9, 2025, 16:22 PM -
Estimated Healthcare Resource Utilization and Costs Associated With Semaglutide Life Expectancy Gains in a Real-World Population With CVD and Overweight or Obesity in the United Kingdom
Sep 9, 2025, 16:22 PM -
Measuring the Disease Burden and Quality of Life From the Schizophrenia Caregivers’ Perspective
Sep 9, 2025, 16:22 PM